AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9383177 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment (single drug or combination) for 1 month
Number of subjects: 33
Study 9383177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline after lowering arterial pressure
Number of subjects: 33
Study 9383177 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.3 mg in 100 ml)
Number of subjects: 33
Study 9383177 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (50 mg in 250 ml)
Number of subjects: 33
Study 8281243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (80 mg/day)
Number of subjects: 118
Study 8281243 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (200 mg/day)
Number of subjects: 118
Study 3318432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg once daily at bedtime
Number of subjects: 106
Study 3318432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 31955321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 0
Study 31955321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 30738555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment for 28 weeks (n = 17)
Number of subjects: 31
Study 30738555 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 28 weeks (n = 14)
Number of subjects: 31
Study 30738555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 31
Study 30738555 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 31
Study 28042985 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine annual health examination with functional evaluations, exercise instruction, and nutrition education
Number of subjects: 404
Study 28042985 — intervention group
Group type: COMPARATOR
Intervention: Routine annual health examination
Number of subjects: 404
Study 26319476 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 400
Study 26319476 — intervention group
Group type: COMPARATOR
Intervention: High Ligation and Stripping (HLS)
Number of subjects: 400
Study 24084768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 503
Study 24084768 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 503
Study 21725257 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Baha implant system
Number of subjects: 77
Study 21725257 — intervention group
Group type: COMPARATOR
Intervention: Previous-generation implant system
Number of subjects: 77
Study 19905916 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with self-management plan (ESM)
Number of subjects: 88
Study 19905916 — intervention group
Group type: COMPARATOR
Intervention: Education without self-management plan (E)
Number of subjects: 88
Study 19905916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both E and ESM groups
Number of subjects: 88
Study 16686572 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training at 60% of 1 repetition maximum (1RM) with repetitions to exhaustion
Number of subjects: 0
Study 16686572 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training at 80% of 1 repetition maximum (1RM) with limited repetitions
Number of subjects: 0
Study 16686572 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lactate measurements included in total energy expenditure interpretation
Number of subjects: 0
Study 16686572 — intervention group
Group type: COMPARATOR
Intervention: Oxygen uptake-only measurements
Number of subjects: 0
Study 15016033 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric powered toothbrush
Number of subjects: 24
Study 15016033 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual toothbrush
Number of subjects: 24
Study 11318767 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg once daily in the morning
Number of subjects: 27
Study 11318767 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg once daily in the evening
Number of subjects: 27
Study 11318767 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily
Number of subjects: 27
Study 11318767 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg twice daily
Number of subjects: 27
Study 11318767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9129752 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oxymetazoline (b.i.d. 150 microliters per nostril)
Number of subjects: 50
Study 9129752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oxymetazoline (substituted for vehicle on days 1, 3, and 7)
Number of subjects: 50
Study 9129752 — intervention group
Group type: COMPARATOR
Intervention: Daily vehicle (b.i.d. 150 microliters per nostril)
Number of subjects: 50
Study 7962364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery instructions
Number of subjects: 60
Study 7962364 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal labeling training
Number of subjects: 60
Study 7962364 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning instructions (imagery or verbal labeling)
Number of subjects: 60
Study 3503965 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum physiologic therapy
Number of subjects: 80
Study 3503965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + antihistaminic + nose drops therapy
Number of subjects: 80
Study 3503965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate + antihistaminic + nose drops therapy
Number of subjects: 80
Study 29949052 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class education
Number of subjects: 50
Study 29949052 — intervention group
Group type: COMPARATOR
Intervention: Online education
Number of subjects: 50
Study 29949052 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient willingness
Number of subjects: 50
Study 28259894 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-shift work (NSW)
Number of subjects: 53
Study 28259894 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep
Number of subjects: 53
Study 26028917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and sirolimus
Number of subjects: 28
Study 26028917 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and mycophenolate mofetil
Number of subjects: 28
Study 24684813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat training
Number of subjects: 15
Study 24684813 — intervention group
Group type: COMPARATOR
Intervention: Control group (fifteen iSCI patients)
Number of subjects: 15
Study 22810444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs
Number of subjects: 0
Study 22810444 — intervention group
Group type: EXPERIMENTAL
Intervention: Examples of design adaptations
Number of subjects: 0
Study 22810444 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design
Number of subjects: 0
Study 22810444 — intervention group
Group type: EXPERIMENTAL
Intervention: Designs suitable for exploratory trials, explanatory trials, and trials assessing cost‐effectiveness
Number of subjects: 0
Study 19108001 — intervention group
Group type: EXPERIMENTAL
Intervention: SG 100
Number of subjects: 56
Study 19108001 — intervention group
Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 56
Study 17317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Optec 800 visual acuity device
Number of subjects: 33
Study 17317400 — intervention group
Group type: COMPARATOR
Intervention: ETDRS chart
Number of subjects: 33
Study 15352917 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine
Number of subjects: 12
Study 15352917 — intervention group
Group type: EXPERIMENTAL
Intervention: Almagate
Number of subjects: 12
Study 15352917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12785672 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback (verbal encouragement)
Number of subjects: 77
Study 12785672 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative feedback (algebraic error score)
Number of subjects: 77
Study 12785672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Qualitative and Quantitative feedback
Number of subjects: 77
Study 12785672 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 77
Study 9830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriplegic spinal cord injury (SCI)
Number of subjects: 0
Study 9830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraplegic spinal cord injury (SCI)
Number of subjects: 0
Study 9830255 — intervention group
Group type: COMPARATOR
Intervention: Controls (traumatic injuries other than SCI)
Number of subjects: 0
Study 8083767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% propolis in aqueous alcohol solution
Number of subjects: 27
Study 8083767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% aqueous alcohol
Number of subjects: 27
Study 8083767 — intervention group
Group type: COMPARATOR
Intervention: No mouth rinse
Number of subjects: 27
Study 2520406 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine (20 mg in 50 ml 0.5% lidocaine)
Number of subjects: 12
Study 2520406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (1.25 mg in 50 ml 0.5% lidocaine)
Number of subjects: 12
Study 2520406 — intervention group
Group type: COMPARATOR
Intervention: Control (50 ml 0.5% lidocaine)
Number of subjects: 12
Study 268710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiomed II (coloured, stabilized with SO2)
Number of subjects: 0
Study 268710 — intervention group
Group type: COMPARATOR
Intervention: Histoacryl blue
Number of subjects: 0
Study 268710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiomed III (coloured, without SO2)
Number of subjects: 0
Study 268710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiomed I (without dye, stabilized with SO2)
Number of subjects: 0
Study 31562608 — intervention group
Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg once weekly
Number of subjects: 27
Study 31562608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 27
Study 28619476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexanolone
Number of subjects: 21
Study 28619476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26010524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 103
Study 26010524 — intervention group
Group type: COMPARATOR
Intervention: Patient Education (ED)
Number of subjects: 103
Study 23489465 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (100 mg)/lumefantrine (480 mg) (ASLF FDC)
Number of subjects: 158
Study 23489465 — intervention group
Group type: COMPARATOR
Intervention: Artemether (80 mg)/lumefantrine (480 mg) (AMLF FDC)
Number of subjects: 158
Study 20955637 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of mitomycin C after surgical shave excision
Number of subjects: 20
Study 19344196 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-tip testing (FT)
Number of subjects: 174
Study 19344196 — intervention group
Group type: COMPARATOR
Intervention: Forearm alternative site testing (AST)
Number of subjects: 174
Study 19344196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study 16705054 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at low dose (LD, 0.05 mUxmin(‐1)x100 ml(‐1))
Number of subjects: 19
Study 16705054 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at intermediate dose (ID, 0.15 mUxmin(‐1)x100 ml(‐1))
Number of subjects: 19
Study 16705054 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at high dose (HD, 0.30 mUxmin(‐1)x100 ml(‐1))
Number of subjects: 19
Study 14744846 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-CHO diet (18% fat, 19% protein, 63% carbohydrates, 26 g of fiber per 1000 kcal)
Number of subjects: 34
Study 14744846 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-CHO + EX diet (HI-CHO diet plus endurance exercise 4 d/wk, 45 min/d, at 80% peak oxygen consumption)
Number of subjects: 34
Study 14744846 — intervention group
Group type: COMPARATOR
Intervention: Control diet (41% fat, 14% protein, 45% carbohydrates, and 7 g of fiber per 1000 kcal)
Number of subjects: 34
Study 11525551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicon
Number of subjects: 9
Study 11525551 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSys
Number of subjects: 9
Study 11525551 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratron
Number of subjects: 9
Study 12017933 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer PeroxiCare (52% baking soda, 3% sodium percarbonate)
Number of subjects: 101
Study 12017933 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care (65% baking soda)
Number of subjects: 101
Study 12017933 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological analysis from a 50-subject subset
Number of subjects: 101
Study 8505833 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted enteral feeding tubes
Number of subjects: 39
Study 8505833 — intervention group
Group type: COMPARATOR
Intervention: Unweighted enteral feeding tubes
Number of subjects: 39
Study 8505833 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg in adults, 0.1 mg/kg in children) with unweighted tube
Number of subjects: 39
Study 3710499 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of activated charcoal
Number of subjects: 0
Study 3710499 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 30128932 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and social-cognitive factors (intention, self-efficacy, outcome expectancies, social support, motivation)
Number of subjects: 1973
Study 30128932 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive environment (family and friends avoiding discouragement for healthy eating)
Number of subjects: 1973
Study 26329396 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 432
Study 26329396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 24373390 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives (five types including reward vouchers of differing values, charity donation, participation in a lottery, choices between a lottery and a voucher, and including vouchers of differing values in the test kit)
Number of subjects: 2988
Study 24373390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 2988
Study 21702324 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental stannous-containing sodium fluoride dentifrice (1450 ppm fluoride)
Number of subjects: 81
Study 21702324 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate
Number of subjects: 81
Study 16098233 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRPhe47
Number of subjects: 160
Study 16098233 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HLA-DR antibody
Number of subjects: 160
Study 16098233 — intervention group
Group type: COMPARATOR
Intervention: Anti-HLA-DP antibody
Number of subjects: 160
Study 16098233 — intervention group
Group type: COMPARATOR
Intervention: Anti-HLA-DQ antibody
Number of subjects: 160
Study 16098233 — intervention group
Group type: COMPARATOR
Intervention: HLA-DPGlu69
Number of subjects: 160
Study 11941551 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone plus pyrimethamine (1500 mg orally twice daily + 75 mg per day after a 200‐mg loading dose)
Number of subjects: 39
Study 11941551 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone plus sulfadiazine (1500 mg orally twice daily + 1500 mg 4 times daily)
Number of subjects: 39
Study 11941551 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance phase of atovaquone
Number of subjects: 39
Study 11941551 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-containing regimens
Number of subjects: 39
Study 9861117 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural 0.25% bupivacaine 4‐7 ml h‐1 and morphine 0.16‐0.28 ml h‐1
Number of subjects: 31
Study 9861117 — intervention group
Group type: COMPARATOR
Intervention: Extradural saline and conventional analgesics
Number of subjects: 31
Study 7611794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 3 mg/kg per day
Number of subjects: 61
Study 7611794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.5 mg/kg per day
Number of subjects: 61
Study 7611794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 2229765 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 78
Study 2229765 — intervention group
Group type: COMPARATOR
Intervention: New catheter
Number of subjects: 78
Study 345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg three times daily for three consecutive days)
Number of subjects: 18
Study 345174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical pills taken according to the same schedule)
Number of subjects: 18
Study 31869292 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antimicrobial and surgical interventions for IDU-associated infections
Number of subjects: 0
Study 29023179 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP treatment
Number of subjects: 20
Study 29023179 — intervention group
Group type: COMPARATOR
Intervention: Basal group (no treatment)
Number of subjects: 20
Study 26502012 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term daily azithromycin therapy
Number of subjects: 47
Study 26066644 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan + Calcium Channel Blocker (CCB)
Number of subjects: 4876
Study 26066644 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan + Diuretic
Number of subjects: 4876
Study 26066644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 4876
Study 23017618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150mg twice daily for four weeks
Number of subjects: 55
Study 23017618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23017618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 55
Study 23017618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo
Number of subjects: 55
Study 20581657 — intervention group
Group type: EXPERIMENTAL
Intervention: Edotecarin (J-107088) combined with infusional 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 14
Study 20581657 — intervention group
Group type: EXPERIMENTAL
Intervention: Edotecarin (J-107088)
Number of subjects: 14
Study 20581657 — intervention group
Group type: EXPERIMENTAL
Intervention: Edotecarin (J-107088) combined with infusional 5-FU/LV
Number of subjects: 14
Study 17882235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy for 4 weeks
Number of subjects: 73
Study 17882235 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural summer remission
Number of subjects: 73
Study 16416134 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 50 mg folinic acid and gradually escalated 5-fluorouracil (350-500 mg/m2, days 1-5)
Number of subjects: 93
Study 16416134 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group)
Number of subjects: 93
Study 14667119 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde puncture
Number of subjects: 100
Study 14667119 — intervention group
Group type: COMPARATOR
Intervention: Antegrade puncture
Number of subjects: 100
Study 11064976 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative indwelling bladder catheter
Number of subjects: 652
Study 11064976 — intervention group
Group type: COMPARATOR
Intervention: Postoperative catheterization as necessary
Number of subjects: 652
Study 8823257 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI 10.0 Gy (37 patients)
Number of subjects: 144
Study 8823257 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI 12.5 Gy (23 patients)
Number of subjects: 144
Study 8823257 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI 15.0 Gy (18 patients)
Number of subjects: 144
Study 8823257 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI 17.5 Gy (40 patients)
Number of subjects: 144
Study 8823257 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI 20.0 Gy (26 patients)
Number of subjects: 144
Study 8823257 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 144
Study 8823257 — intervention group
Group type: COMPARATOR
Intervention: Fractionated HBI vs. single high-dose HBI
Number of subjects: 144
Study 1595920 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg bolus injection, followed by a continuous infusion at 200 micrograms.kg‐1.min‐1)
Number of subjects: 36
Study 1595920 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg bolus injection, followed by continuous infusion at 200 micrograms.kg‐1.min‐1)
Number of subjects: 36
Study 1595920 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (50 and 100 micrograms.kg‐1.min‐1)
Number of subjects: 36
Study 1595920 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 36
Study 6205614 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐(3,4‐dimethoxycinnamoyl) anthranilic acid (N‐5')
Number of subjects: 302
Study 6205614 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 302
Study 6205614 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 302
Study 31847913 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation through groups and individual volunteers
Number of subjects: 0
Study 31847913 — intervention group
Group type: EXPERIMENTAL
Intervention: Support services, community group, and volunteer activities
Number of subjects: 0
Study 31847913 — intervention group
Group type: COMPARATOR
Intervention: Support services only
Number of subjects: 0
Study 31847913 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation activities
Number of subjects: 0
Study 29907198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing every other day
Number of subjects: 325